Drug Combination Details
| General Information of the Combination (ID: C69830) | |||||
|---|---|---|---|---|---|
| Name | Phytosphingosine NP Info | + | TNF-related apoptosis inducing ligand Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Anaplastic large cell lymphoma
[ICD-11: 2A90]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | TRAIL-R1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | TRAIL-R2 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Jurkat | CVCL_0065 | T acute lymphoblastic leukemia | Homo sapiens | ||
| Experimental
Result(s) |
Phytosphingosine sensitizes cancer cells to TRAIL through the synergistic up-regulation of DR4 and DR5 in an NF-kappaB-dependent fashion resulting in caspase-8 activation and subsequent mitochondrial dysfunction. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Phytosphingosine in combination with TRAIL sensitizes cancer cells to TRAIL through synergistic up-regulation of DR4 and DR5. Oncol Rep. 2007 Jan;17(1):175-84. | |||
